Wihuri Research Institute, FI-00290, Helsinki, Finland.
Research Program Unit, University of Helsinki, FI-00014, Helsinki, Finland.
Lipids Health Dis. 2018 Dec 13;17(1):285. doi: 10.1186/s12944-018-0930-2.
The focus of studies on high-density lipoproteins (HDL) has shifted from HDL-cholesterol (HDL-C) to HDL function. We recently demonstrated that low USF1 expression in mice and humans associates with high plasma HDL-C and low triglyceride levels, as well as protection against obesity, insulin resistance, and atherosclerosis. Here, we studied the impact of USF1 deficiency on HDL functional capacity and macrophage atherogenic functions, including inflammation, cholesterol efflux, and cholesterol accumulation.
We used a congenic Usf1 deficient mice in C57Bl/6JRccHsd background and blood samples were collected to isolate HDL for structural and functional studies. Lentiviral preparations containing the USF1 silencing shRNA expression vector were used to silence USF1 in human THP-1 and Huh-7 cells. Cholesterol efflux from acetyl-LDL loaded THP-1 macrophages was measured using HDL and plasma as acceptors. Gene expression analysis from USF1 silenced peritoneal macrophages was carried out using Affymetrix protocols.
We show that Usf1 deficiency not only increases HDL-C levels in vivo, consistent with elevated ABCA1 protein expression in hepatic cell lines, but also improves the functional capacity of HDL particles. HDL particles derived from Usf1 deficient mice remove cholesterol more efficiently from macrophages, attributed to their higher contents of phospholipids. Furthermore, silencing of USF1 in macrophages enhanced the cholesterol efflux capacity of these cells. These findings are consistent with reduced inflammatory burden of USF1 deficient macrophages, manifested by reduced secretion of pro-inflammatory cytokines MCP-1 and IL-1β and protection against inflammation-induced macrophage cholesterol accumulation in a cell-autonomous manner.
Our findings identify USF1 as a novel factor regulating HDL functionality, showing that USF1 inactivation boosts cholesterol efflux, reduces macrophage inflammation and attenuates macrophage cholesterol accumulation, linking improved macrophage cholesterol metabolism and inflammatory pathways to the antiatherogenic function of USF1 deficiency.
对高密度脂蛋白(HDL)的研究重点已从 HDL 胆固醇(HDL-C)转移到 HDL 功能。我们最近证明,小鼠和人类中 USF1 表达水平降低与血浆 HDL-C 升高和甘油三酯水平降低以及肥胖、胰岛素抵抗和动脉粥样硬化的保护作用有关。在这里,我们研究了 USF1 缺乏对 HDL 功能能力和巨噬细胞致动脉粥样硬化功能的影响,包括炎症、胆固醇流出和胆固醇积累。
我们使用了在 C57Bl/6JRccHsd 背景下缺乏 USF1 的同基因小鼠,收集血液样本以分离 HDL 进行结构和功能研究。使用含有 USF1 沉默 shRNA 表达载体的慢病毒制剂沉默人 THP-1 和 Huh-7 细胞中的 USF1。使用 HDL 和血浆作为受体测量载有乙酰 LDL 的 THP-1 巨噬细胞中的胆固醇流出。使用 Affymetrix 方案对 USF1 沉默的腹腔巨噬细胞进行基因表达分析。
我们表明,Usf1 缺乏不仅增加了体内的 HDL-C 水平,与肝细胞系中 ABCA1 蛋白表达升高一致,而且还提高了 HDL 颗粒的功能能力。来自 Usf1 缺乏小鼠的 HDL 颗粒从巨噬细胞中更有效地去除胆固醇,这归因于它们更高的磷脂含量。此外,巨噬细胞中 USF1 的沉默增强了这些细胞的胆固醇流出能力。这些发现与 USF1 缺乏的巨噬细胞炎症负担减轻一致,表现为促炎细胞因子 MCP-1 和 IL-1β 的分泌减少,并且以细胞自主的方式保护免受炎症诱导的巨噬细胞胆固醇积累。
我们的研究结果将 USF1 确定为调节 HDL 功能的新因子,表明 USF1 失活可促进胆固醇流出,减少巨噬细胞炎症并减轻巨噬细胞胆固醇积累,将改善的巨噬细胞胆固醇代谢和炎症途径与 USF1 缺乏的抗动脉粥样硬化功能联系起来。